in addition [10%:150 mg have not been shown to have an increased benefit. Shift-work disorder: Oral: 150 mg given once daily ~1 hour prior to work shift Dosing: Geriatric Refer to adult dosing. Consider lower initial dosage. Dosing: Renal Impairment There are no dosage adjustments provided in the manufacturer's labeling. Dosing: Hepatic Impairment Mild to moderate hepatic impairment: No dosage adjustment necessary. Severe hepatic impairment: The manufacturer recommends a reduced dose due to decreased clearance and increased steady-state concentration of modafinil in this patient population. Administration May be administered without regard to food. Storage Store at 20 C to 25 C (68 F to 77 F). Drug Interactions Acebrophylline: May enhance the stimulatory effect of CNS Stimulants. Avoid combination Alcohol (Ethyl): May diminish the therapeutic effect of Armodafinil. Avoid combination ARIPiprazole: Armodafinil may decrease the serum concentration of ARIPiprazole. Monitor therapy AtoMOXetine: May enhance the hypertensive effect of Sympathomimetics. AtoMOXetine may enhance the tachycardic effect of Sympathomimetics. Monitor therapy Bosentan: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Monitor therapy Cannabinoid-Containing Products: May enhance the tachycardic effect of Sympathomimetics. Exceptions: Cannabidiol. Monitor therapy Cilostazol: CYP2C19 Inhibitors may increase the serum concentration of Cilostazol. Management: Consider reducing the cilostazol dose to 50 mg twice daily in patients who are also receiving inhibitors of CYP2C19. Consider therapy modification CloZAPine: CYP3A4 Inducers (Weak) may decrease the serum concentration of CloZAPine. Monitor therapy Cocaine: May enhance the hypertensive effect of Sympathomimetics. Management: Consider alternatives to use of this combination when possible. Monitor closely for substantially increased blood pressure or heart rate and for any evidence of myocardial ischemia with concurrent use. Consider therapy modification CycloSPORINE (Systemic): Armodafinil may decrease the serum concentration of CycloSPORINE (Systemic). Monitor therapy CYP3A4 Inducers (Moderate): May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Monitor therapy CYP3A4 Inducers (Strong): May increase the metabolism of CYP3A4 Substrates (High risk with Inducers). Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling. Consider therapy modification Dabrafenib: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Seek alternatives to the CYP3A4 substrate when possible. If concomitant therapy cannot be avoided, monitor clinical effects of the substrate closely (particularly therapeutic effects). Consider therapy modification Deferasirox: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Monitor therapy Doxofylline: Sympathomimetics may enhance the adverse/toxic effect of Doxofylline. Monitor therapy Enzalutamide: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Concurrent use of enzalutamide with CYP3A4 substrates that have a narrow therapeutic index should be avoided. Use of enzalutamide and any other CYP3A4 substrate should be performed with caution and close monitoring. Consider therapy modification Estrogen Derivatives (Contraceptive): Armodafinil may decrease the serum concentration of Estrogen Derivatives (Contraceptive). Management: The manufacturer recommends that patients use nonhormonal contraceptives, in addition to or in place of hormonal contraceptives, during and for one month following treatment with armodafinil. Consider therapy modification Guanethidine: May enhance the arrhythmogenic effect of Sympathomimetics. Guanethidine may enhance the hypertensive effect of Sympathomimetics. Monitor therapy HYDROcodone: CYP3A4 Inducers (Weak) may decrease the serum concentration of HYDROcodone. Monitor therapy Iobenguane I 123: Sympathomimetics may diminish the therapeutic effect of Iobenguane I 123. Avoid combination Linezolid: May enhance the hypertensive effect of Sympathomimetics. Management: Reduce initial doses of sympathomimetic agents, and closely monitor for enhanced pressor response, in patients receiving linezolid. Specific dose adjustment recommendations are not presently available. Consider therapy modification Mitotane: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Doses of CYP3A4 substrates may need to be adjusted substantially when used in patients being treated with mitotane. Consider therapy modification NiMODipine: CYP3A4 Inducers (Weak) may decrease the serum concentration of NiMODipine. Monitor therapy Pitolisant: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Combined use of pitolisant with a CYP3A4 substrate that has a narrow therapeutic index should be avoided. Other CYP3A4 substrates should be monitored more closely when used with pitolisant. Consider therapy modification Sarilumab: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Monitor therapy Siltuximab: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Monitor therapy St John's Wort: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling. Consider therapy modification Sympathomimetics: May enhance the adverse/toxic effect of other Sympathomimetics. Monitor therapy Tedizolid: May enhance the hypertensive effect of Sympathomimetics. Tedizolid may enhance the tachycardic effect of Sympathomimetics. Monitor therapy Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Monitor therapy Adverse Reactions >10%: Central nervous system: Headache (14% to 23%; dose related) 1% to 10%: Cardiovascular: Palpitations (2%), increased heart rate (1%) Central nervous system: Insomnia (4% to 6%; dose related), dizziness (5%), anxiety (4%), depression (1% to 3%; dose related), fatigue (2%), agitation (1%), depressed mood (1%), lack of concentration (1%), migraine (1%), nervousness (1%), pain (1%), paresthesia (1%) Dermatologic: Skin rash (1% to 4%; dose related), contact dermatitis (1%), diaphoresis (1%) Endocrine & metabolic: Increased gamma-glutamyl transferase (1%), increased thirst (1%) Gastrointestinal: Nausea (6% to 9%; dose related), xerostomia (2% to 7%; dose related), diarrhea (4%), dyspepsia (2%), upper abdominal pain (2%), anorexia (1%), constipation (1%), decreased appetite (1%), loose stools (1%), vomiting (1%) Hypersensitivity: Seasonal allergy (1%) Neuromuscular & skeletal: Tremor (1%) Renal: Polyuria (1%) Respiratory: Dyspnea (1%), flu-like symptoms (1%) Miscellaneous: Fever (1%)] Drug Status Rx Availability Prescription only C Pregnancy Category Risk cannot be ruled out 4 CSA Schedule Some potential for abuse Approval History Drug history at FDA Armodafinil Rating 284 User Reviews 7.5 /10 284 User Reviews 7.5 Rate it! Manufacturers Breckenridge Pharmaceutical, Inc. Lupin Pharmaceuticals, Inc. Mylan Pharmaceuticals Inc. Sandoz Inc. Teva Pharmaceuticals USA, Inc. More... Drug Class CNS stimulants Related Drugs CNS stimulants Adderall , phentermine , methylphenidate , Vyvanse , Ritalin , modafinil Narcolepsy Adderall , methylphenidate , Ritalin , modafinil , Concerta , dextroamphetamine , Provigil , More... Shift Work Sleep Disorder modafinil , Provigil , Nuvigil , More... Obstructive Sleep Apnea / Hypopnea Syndrome modafinil , Provigil , Nuvigil , More... Armodafinil Images Armodafinil systemic 50 mg (M A31) View all images to make use of
kind of Armodafinil twine
EmoticonEmoticon